Beauty Health (SKIN) Scheduled to Post Earnings on Thursday

Beauty Health (NASDAQ:SKIN) will be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Beauty Health to post earnings of ($0.14) per share for the quarter. Beauty Health has set its Q1 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The company had revenue of $96.80 million for the quarter, compared to analysts’ expectations of $87.22 million. During the same period last year, the firm earned $0.03 earnings per share. Beauty Health’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts expect Beauty Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beauty Health Stock Down 1.7 %

Beauty Health stock opened at $3.37 on Wednesday. Beauty Health has a 1-year low of $1.35 and a 1-year high of $11.16. The company has a debt-to-equity ratio of 12.43, a current ratio of 6.07 and a quick ratio of 5.28. The stock has a market cap of $415.96 million, a PE ratio of -4.38 and a beta of 1.13. The stock’s fifty day moving average is $3.69 and its two-hundred day moving average is $3.30.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Piper Sandler restated an “underweight” rating and issued a $3.00 price target (up from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. TD Cowen lifted their target price on Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 13th. Canaccord Genuity Group lifted their target price on Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, March 14th. Stifel Nicolaus reiterated a “hold” rating and set a $4.00 target price (up previously from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Finally, DA Davidson reiterated a “buy” rating and set a $5.00 target price on shares of Beauty Health in a research report on Friday, March 15th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.50.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.